Andrea Apolo, MD from the National Cancer Institute at the Memorial Sloan-Kettering Cancer Center, Bethesda, MD emphasizes the importance of clinical trials, and the need for more eligible patients to enroll and participate. A clinical trial is the most informative route of investigating drug-disease interactions.
The larger the patient cohort, the more potential information it can give researchers about drug-disease interactions and the more valid the findings of the trial. Therefore, it is crucial that physicians encourage their patients to participate, as there is no disadvantage to the patient in terms of efficacy and toxicity when compared to standard chemotherapy. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL